Ultra-deep sequencing of paired plasma-circulating free DNA and white blood cells allows the identification of tumor-derived somatic mutations with high accuracy by filtering out variants consistent with clonal hematopoiesis.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Cell-free DNA analysis in current cancer clinical trials: a review
British Journal of Cancer Open Access 13 January 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Razavi, P. et al. Nat. Med. https://doi.org/10.1038/s41591-019-0652-7 (2019).
Heitzer, E., Haque, I. S., Roberts, C. E. S. & Speicher, M. R. Nat. Rev. Genet. 20, 71–88 (2019).
Steensma, D. P. et al. Blood 126, 9–16 (2015).
Lui, Y. Y. et al. Clin. Chem. 48, 421–427 (2002).
Moss, J. et al. Nat. Commun. 9, 5068 (2018).
Snyder, M. W. et al. Cell 164, 57–68 (2016).
Hu, Y. et al. Clin. Cancer Res. 24, 4437–4443 (2018).
Liu, J. et al. Ann. Oncol. 30, 464–470 (2018).
Takahashi, K. et al. Lancet Oncol. 18, 100–111 (2017).
Gillis, N. K. et al. Lancet Oncol. 18, 112–121 (2017).
Jaiswal, S. et al. N. Engl. J. Med. 377, 111–121 (2017).
Bolton, K. L. et al. J. Clin. Oncol. 37, 7–11 (2019).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
B.B. has received honoraria for a speaker, consultancy or advisory role from Astra-Zeneca, Biocartis, Merck Serono, Novartis, Qiagen, Hoffman–La Roche, ThermoFisher, Pfizer and Bristol-Myers Squibb. C.M. declares institutional research funding from Amgen, Bayer, Biocartis, BMS, Merck Serono, Roche, and Sanofi Aventis as well as advisory board or speaker fees from Amgen, Biocartis, Merck Serono, Roche, Symphogen, Guardant Health, Seattle Genetics and Sysmex.
Rights and permissions
About this article
Cite this article
Bellosillo, B., Montagut, C. High-accuracy liquid biopsies. Nat Med 25, 1820–1821 (2019). https://doi.org/10.1038/s41591-019-0690-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-019-0690-1
This article is cited by
-
Microfluidics engineering towards personalized oncology—a review
In vitro models (2023)
-
Cell-free DNA analysis in current cancer clinical trials: a review
British Journal of Cancer (2022)